For a long time, the shares of Bachem only knew the direction upwards.Then the peptide manufacturer came to an end in mid -October with a capital increase.The stock broke in because investors sold their shares because of the watering down.Since then the course has weakened and is further crumbled.He is now noted for a good quarter below the annual high of CHF 855 from CHF 15.October.
Bachem share in the past three years, graphic: cash.ch.
This means that the share is cheaply valued after the latest course correction, it says on the market.Because the prospects for the pharmaceutical suppliers in general and for Bachem in particular are promising.This is also the opinion of Mirabaud.The asset manager has therefore increased the price target to a total of CHF 1,000 of CHF 600 and thus set a true milestone.In addition, the purchase recommendation is confirmed.
He has increased his estimates by up to 17 percent, analyst Daniel Jelovcan says his decision.The "new" Oligonucleotide sales goal of CHF 100 million is likely to be reached in 2022 or 2023.
(AWP)
How to get the perfect look for Cos...
Test winner at Stiftung Warentest:...
Cream for Rosacea: The Best Creams
Dry elbows: This is how brittle ski...